Paris and Cambridge, MA. June 2, 2025. Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis (SM), a rare ...

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, the companies said today, in a deal designed to expand the buyer’s rare immunological disease portfolio with an ...

BeOne Medicines (ONC) announced an update on their ongoing clinical study. BeOne Medicines is running an early-stage trial to test a new cancer drug, BG-75098, in adults with advanced solid tumors.

LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. On Wednesday, scientists reported interim results from an early study of ...

The field of retinal imaging has long provided a unique, non-invasive window to systemic vascular health, with microvascular ...

Modern medicine is more advanced than ever, yet clinical care still leans heavily on what is, in practice, informed guesswork. Doctors make the most probable diagnosis, select the therapy most likely ...

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, ...